2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10616
    Salusin-α 624735-22-4 98%
    Salusin-α is an endogenous bioactive peptide with hemodynamic and cell proliferation activities. Salusin-α can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate, but its effect is weaker than that of Salusin-β (HY-P10617). Salusin-α has potential application value in cardiovascular disease research.
    Salusin-α
  • HY-P10617
    Salusin-β 624735-23-5 98%
    Salusin-β is an endogenous bioactive peptide with significant hemodynamic and mitogenic activity. Salusin-β can stimulate the proliferation of quiescent vascular smooth muscle cells (VSMCs) and fibroblasts, leading to a rapid and significant decrease in blood pressure and heart rate. In addition, Salusin-β can stimulate the release of arginine vasopressin from the pituitary gland in rats. This makes Salusin-β have important application potential in cardiovascular disease research.
    Salusin-β
  • HY-P10621
    SHLP-1 98%
    SHLP-1 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-1 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer.
    SHLP-1
  • HY-P10623
    SHLP-4 1191923-94-0 98%
    SHLP-4 is a mitochondrial derived peptide, a biologically active microprotein encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-4 increases the proliferation of mouse NIT-1 cells. SHLP-4 can be used in the study of diabetes and cardiovascular diseases.
    SHLP-4
  • HY-P10624
    SHLP-5 1191923-95-1 98%
    SHLP-5 is a mitochondrial-derived peptide, a biologically active microprotein encoded by the 16s ribosomal RNA (MT-RNR2) gene. SHLP-5 can be used in the research of diabetes, Alzheimer's disease, cardiovascular disease and prostate cancer.
    SHLP-5
  • HY-P10640
    [Sar1,Thr8]-Angiotensin II 53632-49-8 98%
    [Sar1,Thr8]-Angiotensin II is a potent angiotensin II antagonist. [Sar1,Thr8]-Angiotensin II does not alter cardiac performance. [Sar1,Thr8]-Angiotensin II might be safe for patients with cardiac disease.
    [Sar1,Thr8]-Angiotensin II
  • HY-P10645
    T9 peptide 1098005-45-8 98%
    T9 peptide (SKTFNTHPQSTP) is a muscle targeting peptide. T9 peptide binds strongly to C2C12 myoblasts. T9 peptide is capable of increased specificity for the heart and quadriceps muscles if conjugated to oligonucleotides without a similar effect in targeting to the kidney, liver, and diaphragm.
    T9 peptide
  • HY-P1065A
    Apelin-36(rat, mouse) TFA 98%
    Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) TFA blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
    Apelin-36(rat, mouse) TFA
  • HY-P10709
    CREKA peptide 847058-45-1 98%
    CREKA peptide is a short peptide sequence, belonging to self-assembling peptides (SAPs), which can self-assemble into functional nanostructures, typically nanofibers, under physiological conditions. CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity.
    CREKA peptide
  • HY-P10720
    C-Type Natriuretic Peptide (1-53), Porcine, Rat,mouse 129405-72-7 98%
    C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse is an activator of particulate guanylate cyclase B (pGC-B), which is highly expressed in endothelial cells, kidneys, and the heart. C-Type Natriuretic Peptide (1-53), Porcine, Rat, mouse can mediate a potent anti-fibrotic effect in human cardiac and renal fibroblasts by generating the second messenger cGMP.
    C-Type Natriuretic Peptide (1-53), Porcine, Rat,mouse
  • HY-P10728
    B7-33 1818415-56-3 98%
    B7-33 is a single-chain relaxin mimetic. B7-33 is a selective relaxin receptor 1 (RXFP1) agonist. B7-33 binds to RXFP1 and preferentially activates thepERK pathway over cAMP in cells (with RXFP1 expression). B7-33 is an anti-fibrotic agent. B7-33 has cardioprotective effects.
    B7-33
  • HY-P10770
    P-ESBP-DOX 98%
    P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature.
    P-ESBP-DOX
  • HY-P10773
    CTP-amiodarone 98%
    CTP-amiodarone is a cell-penetrating conjugate of cardiomyocyte targeting peptide and Amiodarone (HY-14187). CTP-amiodarone exhibits antiarrhythmic efficacy through block of Na+, K+, Ca2+ channels and β-adrenergic receptors.
    CTP-amiodarone
  • HY-P10791
    YYLLVR 3060796-96-2 98%
    YYLLVR is an angiotensin-converting enzyme (ACE) inhibitory peptide with an inhibitory rate of 89.10%. YYLLVR has a lower binding energy for ACE of -35.98 kcal/mol. YYLLVR can be used in the study of hypertensive diseases.
    YYLLVR
  • HY-P10797
    TAT-N24 98%
    TAT-N24 is a cell-permeable TAT peptide as a p55PIK signaling inhibitor. TAT-N24 is effective for corneal neovascularization (CNV) and ocular inflammation by inhibiting the HIF-1α/NF-κB signaling pathway in corneal suture (CS). TAT-N24 also inhibits corneal neovascularization.
    TAT-N24
  • HY-P10808
    RSRGVFF 98%
    RSRGVFF (FOXP3 inhibitor P60) is a mixed-type angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, boasting an IC50 value of 5.01 μM. RSRGVFF is capable of binding to both active and non-active sites of ACE and its substrate HHL complex, thus reducing the catalytic activity of ACE. RSRGVFF can be further utilized for research on lowering hypertension.
    RSRGVFF
  • HY-P10821
    Myr-Tat-PKCβII 98%
    Myr-Tat-PKCβII is a cell permeable protein kinase C β II peptide inhibitor. Myr-Tat-PKCβII mitigates the generation of reactive oxygen species in rat ex-vivo and porcine in-vivo ischemia-reperfusion injury.
    Myr-Tat-PKCβII
  • HY-P10833
    C-VGB3 98%
    C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer.
    C-VGB3
  • HY-P10846
    HYNIC-CTP 98%
    HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide 99mTc through HYNIC acting as a chelator, forming 99mTc-HYNIC-CTP. 99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases.
    HYNIC-CTP
  • HY-P10860
    cMCoFx1 2853605-24-8 98%
    cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic.
    cMCoFx1
Cat. No. Product Name / Synonyms Application Reactivity